Literature DB >> 2437198

Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.

J R Ortaldo, C Woodhouse, A C Morgan, R B Herberman, D A Cheresh, R Reisfeld.   

Abstract

We examined purified human large granular lymphocytes, peripheral monocytes, and T cells for their ability to mediate antibody-dependent cellular cytotoxicity (ADCC) with murine monoclonal antibodies. We also evaluated the effects of pretreatment of cells with interleukin 2 and interferon to augment ADCC activity. MB3.6, a murine monoclonal antibody directed against the GD3 ganglioside, induced high levels of ADCC. This ADCC was mediated predominantly, if not completely, by human killer cells (large granular lymphocytes) whereas other effector cell populations demonstrated no significant cytotoxic activity in 6- or 18-hr assays. The IgG2a an anti-melanoma antibody 9.2.27 generated low or no ADCC with most normal donors or melanoma patients. IL 2 was a very potent booster of ADCC activity. Interferon alpha also was effective, whereas interferon gamma did not augment but rather inhibited reactivity. We tested a large panel of antibodies of various isotype against colon carcinoma cells and found that gamma-3 isotype antibodies more frequently generated ADCC and produced higher levels of cytotoxic activity than did IgG1 or IgG2 antibodies. It appears that a variety of parameters can affect ADCC reactions, including the type of effector cell and its level of activation, the isotype of the antibody, and properties of the target cell line such as its susceptibility to lysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2437198

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization.

Authors:  P A Broliden; K Ljunggren; J Hinkula; E Norrby; L Akerblom; B Wahren
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  Anti-idiotypic monoclonal antibody to a T-cell chronic lymphatic leukemia. Characterization of the antibody, in vitro effector functions and results of therapy.

Authors:  C H Janson; M J Tehrani; H Mellstedt; H Wigzell
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.

Authors:  Emiliano Cocco; Joyce Varughese; Natalia Buza; Stefania Bellone; Ken-Yu Lin; Marta Bellone; Paola Todeschini; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Luisa Carrara; Renata Tassi; Sergio Pecorelli; Charles J Lockwood; Alessandro D Santin
Journal:  Clin Exp Metastasis       Date:  2011-07-02       Impact factor: 5.150

4.  Use of anti-HLA antibodies to mask major histocompatibility complex gene products on tumor cells can enhance susceptibility of these cells to lysis by natural killer cells.

Authors:  P I Lobo; C E Spencer
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

5.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

6.  Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

Authors:  G Masucci; P Wersäll; P Ragnhammar; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

Authors:  Karim El-Sahwi; Stefania Bellone; Emiliano Cocco; Francesca Casagrande; Marta Bellone; Maysa Abu-Khalaf; Natalia Buza; Fattaneh A Tavassoli; Pei Hui; Dominik Rüttinger; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

8.  Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A.

Authors:  Y Haga; C L Sivinski; D Woo; M A Tempero
Journal:  Int J Pancreatol       Date:  1994-02

9.  Human recombinant anti-thyroperoxidase autoantibodies: in vitro cytotoxic activity on papillary thyroid cancer expressing TPO.

Authors:  S A Rebuffat; M Morin; B Nguyen; F Castex; B Robert; S Péraldi-Roux
Journal:  Br J Cancer       Date:  2010-02-09       Impact factor: 7.640

Review 10.  Chemotherapy and immunotherapy of colorectal cancer.

Authors:  G Masucci; P Ragnhammar; J E Frödin; A L Hjelm; P Wersäll; J Fagerberg; A Osterborg; H Mellstedt
Journal:  Med Oncol Tumor Pharmacother       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.